Literature DB >> 15494901

Mass antibiotic treatment and community protection in trachoma control programs.

Jaya D Chidambaram1, Muluken Melese, Wondu Alemayehu, Elizabeth Yi, Tisha Prabriputaloong, David C Lee, Vicky Cevallos, Zhaoxia Zhou, John P Whitcher, Bruce D Gaynor, Thomas M Lietman.   

Abstract

Azithromycin is highly effective against trachoma, but the practical difficulties of community-wide distribution often leave many individuals untreated. We demonstrate, after mass azithromycin treatment of a population in Ethiopia, an indirect protective effect that occurred among untreated children who resided in villages in which most individuals had been treated. Similarities with the indirect protection within a treated community (i.e., "herd protection") that has been observed in vaccination programs are discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15494901     DOI： 10.1086/424747

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

1.  Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.

Authors:  Jon L Yang; Julius Schachter; Jeanne Moncada; Dereje Habte; Mulat Zerihun; Jenafir I House; Zhaoxia Zhou; Kevin C Hong; Kathryn Maxey; Bruce D Gaynor; Thomas M Lietman
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

2.  Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial.

Authors:  Catherine E Oldenburg; Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Bruce D Gaynor; Jeremy D Keenan; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

3.  Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial.

Authors:  Isabelle Cochereau; Pablo Goldschmidt; André Goepogui; Tayyab Afghani; Laurent Delval; Pascale Pouliquen; Tristan Bourcier; Pierre-Yves Robert
Journal:  Br J Ophthalmol       Date:  2006-09-27       Impact factor: 4.638

Review 4.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 5.  Herd Protection from Drinking Water, Sanitation, and Hygiene Interventions.

Authors:  James A Fuller; Joseph N S Eisenberg
Journal:  Am J Trop Med Hyg       Date:  2016-09-06       Impact factor: 2.345

6.  Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial.

Authors:  Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Bruce D Gaynor; Jeremy D Keenan; Thomas M Lietman; Catherine E Oldenburg
Journal:  Br J Ophthalmol       Date:  2017-09-11       Impact factor: 4.638

7.  Collateral benefits arising from mass administration of azithromycin in the control of active trachoma in resource limited settings.

Authors:  Gabriel Kigen; Joseph Rotich; Jefitha Karimurio; Hillary Rono
Journal:  Pan Afr Med J       Date:  2014-11-07

8.  Mass antibiotic treatment alone does not eliminate ocular chlamydial infection.

Authors:  Paul M Emerson; Jeremiah Ngondi
Journal:  PLoS Negl Trop Dis       Date:  2009-03-31

9.  A rationale for continuing mass antibiotic distributions for trachoma.

Authors:  Kathryn J Ray; Travis C Porco; Kevin C Hong; David C Lee; Wondu Alemayehu; Muluken Melese; Takele Lakew; Elizabeth Yi; Jenafir House; Jaya D Chidambaram; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  BMC Infect Dis       Date:  2007-08-07       Impact factor: 3.090

10.  Antibiotic use as a tragedy of the commons: a cross-sectional survey.

Authors:  Kieran S O'Brien; Seth Blumberg; Wayne T A Enanoria; Sarah Ackley; Nicolas Sippl-Swezey; Thomas M Lietman
Journal:  Comput Math Methods Med       Date:  2014-01-22       Impact factor: 2.238
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.